Comparison of 24-hour glycemic excursions in patients with type 2 diabetes receiving additional anti-diabetic agents, acarbose versus sitagliptin, by using continuous glucose monitoring (CGM)

Comparison of 24-hour glycemic excursions in patients with type 2 diabetes receiving additional anti-diabetic agents, acarbose versus sitagliptin, by using continuous glucose monitoring (CGM) - Acarbose versus sitagliptin, by using continuous glucose monitoring (CGM)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004744

Enrollment

Registered

2010-12-17

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

day1 conventional therapy day2 Addition of acarbose(300 mg/day) to the conventional therapy day3 Addition of sitagliptin (50 mg/day) to the conventional therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who were admitted into the Yokohama-City University Hospital

Exclusion criteria

Exclusion criteria: 1,Subjects who have already been treated with insuln, alfa-glucosidase inhibitor or DPP4 inhibitor. 2,Subjects who are hypersensitive to this medicine and/or contaminants of this medicine. 3,Any condition that the investigator considers a potential obstacle to trial participation

Design outcomes

Primary

Measure	Time frame
Changes in the parameters related to glucose profile of the subjects when receiving additional anti-diabetic agents(average glucose, maximum and minimum glucose, area under the curve, standard deviation, mean amplitude of glycemic excursions)	—

Secondary

Measure	Time frame
Frequency of hypoglycemia	—

Countries

Japan

Contacts

Public ContactKaori Kikuchi

Graduate School of Medicine, Yokohama City University Department of Endocrinology and Metabolism

t086028f@yokohama-cu.ac.jp045-787-2639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026